Anti-HLA-B7 Purified

Anti-HLA-B7 Purified
Regulatory status
RUO
Antigen
HLA-B7
Clone
BB7.1
Format
Purified
Reactivity
Non-human primates, Human
Application
FC (QC tested)
Variant
0.1 mg
11-547-C100
Out of stock
140.00 USD

0.025 mg
11-547-C025
Out of stock
70.00 USD
Variant
0.1 mg
11-261-C100
In stock
140.00 USD

0.1 mg
11-261-C100
In stock
70.00 USD
Product details
References
Isotype
Mouse IgG1
Specificity
The mouse monoclonal antibody BB7.1 recognizes an extracellular antigen of HLA-B7 antigen. Although highly specific, it can cross-react with HLA-B42 antigen.
Application
FC (QC tested)
Reactivity
Non-human primates, Human
Immunogen
Papain solubilised HLA-A2, B7
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

General references:

Harjacek M, Margetić T, Kerhin-Brkljacić V, Martinez N, Grubić Z: HLA-B*27/HLA-B*07 in combination with D6S273-134 allele is associated with increased susceptibility to juvenile spondyloarthropathies. Clin Exp Rheumatol. 2008 May-Jun;26(3):498-504.
PubMed
Wang SS, Wheeler CM, Hildesheim A, Schiffman M, Herrero R, Bratti MC, Sherman ME, Alfaro M, Hutchinson ML, Morales J, Lorincz A, Burk RD, Carrington M, Erlich HA, Apple RJ: Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis. 2001 Nov 15;184(10):1310-4.
PubMed
Grunewald J, Eklund A, Olerup O: Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med. 2004 Mar 15;169(6):696-702.
PubMed
Bhattacharya P, Sengupta S: Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B*07 and homozygosity of HLA-DQB1*03. Tissue Antigens. 2007 Oct;70(4):283-93.
PubMed

Product specific references:

Nabel GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao X, Huang L, Shu S, Gordon D, Chang AE: Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11307-11.
PubMed
Worley BS, van den Broeke LT, Goletz TJ, Pendleton CD, Daschbach EM, Thomas EK, Marincola FM, Helman LJ, Berzofsky JA: Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 2001 Sep 15;61(18):6868-75.
PubMed
Storkus WJ, Alexander J, Payne JA, Dawson JR, Cresswell P: Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2361-4.
PubMed
de la Salle H, Saulquin X, Mansour I, Klayme S, Fricker D, Zimmer J, Cazenave JP, Hanau D, Bonneville M, Houssaint E, Lefranc G, Naman R: Asymptomatic deficiency in the peptide transporter associated to antigen processing (TAP). Clin Exp Immunol. 2002 Jun;128(3):525-31.
PubMed
Lo Monaco E, Sibilio L, Melucci E, Tremante E, Suchànek M, Horejsi V, Martayan A, Giacomini P: HLA-E: strong association with beta2-microglobulin and surface expression in the absence of HLA class I signal sequence-derived peptides. Immunol. 2008 Oct 15;181(8):5442-50.
PubMed
Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W: Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS. Mol Cell Proteomics. 2005 Dec;4(12):1888-97.
PubMed
Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M: Immunogenic HLA-B7-restricted peptides of hTRT. Int Immunol. 2006 Dec;18(12):1707-18.
PubMed
Rini BI, Selk LM, Vogelzang NJ: Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res. 1999 Oct;5(10):2766-72.
PubMed
Variant
0.1 mg
11-547-C100
Out of stock
140.00 USD

0.025 mg
11-547-C025
Out of stock
70.00 USD
Variant
0.1 mg
11-261-C100
In stock
140.00 USD

0.1 mg
11-261-C100
In stock
70.00 USD